ViraCyte Announces Positive Phase 2 Trial Results

ViraCyte today announced publication of positive data from a Phase 2 clinical trial evaluating its most advanced T-cell immunotherapy product, Viralym-M. The results were reported by ViraCyte lead investigators at Baylor College of Medicine in the Journal of Clinical Oncology.

ViraCyte Awarded $8.99M from the Cancer Prevention and Research Institute of Texas

ViraCyte today announced notification of funding approval for a Product Development Research grant totaling $8.99 million by the Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee to support the clinical development of the Company’s lead product, Viralym-M – a “ready to administer” multivirus-specific T cell immunotherapy.

ViraCyte Enters Exclusive License Agreement with Baylor College of Medicine for T Cell Immunotherapies Targeting Viruses

ViraCyte, LLC today announced that it has exercised its exclusive option with Baylor College of Medicine (Baylor) to license Baylor's virus-specific T cell therapy technology for the prevention and/or treatment of viral infections.

ViraCyte Completes Phase 1 Clinical Trial of Viralym-C

ViraCyte, LLC today announced the successful completion of a Phase I clinical trial using Viralym-C, a “ready to administer” T cell immunotherapy product for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) recipients.

ViraCyte Awarded $3.75M from NIH and FDA to Advance T Cell Immunotherapies

ViraCyte, LLC today announced that it has been awarded $3.75M from National Institutes of Health (NIH) and the Food and Drug Administration (FDA) to advance its T cell immunotherapies.

ViraCyte Receives Orphan Drug Designation for Viralym-C

ViraCyte, LLC announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Viralym-C, a ready to administer T cell immunotherapy product for the treatment of cytomegalovirus (CMV) in severely immunocompromised patients.

ViraCyte Granted U.S. FDA Fast Track Designation for Viralym-C

ViraCyte, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Viralym-C, ViraCyte's T cell immunotherapy product designed to treat refractory cytomegalovirus (CMV) infections in patients following a stem cell transplant.

ViraCyte Announces Oral Presentations on Clinical Trial Results at the 58th American Society of Hematology Annual Meeting

ViraCyte, LLC announced today that two abstracts regarding the Company's lead product candidates, Viralym-C and Viralym-M, were selected for oral presentations at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego, California on December 3-6.

ViraCyte Appoints Dr. Brett Giroir as President and Chief Executive Officer

ViraCyte, LLC, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections, today announced the appointment of Brett P. Giroir, M.D. as President and Chief Executive Officer, effective immediately.

ViraCyte Selected as a Resident Company at JLABS @ TMC

Johnson & Johnson Innovation Unveils JLABS @ TMC to Help Catalyze Early Stage Research through to Commercialization for Healthcare Solutions in Houston